ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
131.29
-1.71
( -1.29% )
Updated: 14:56:36

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
131.29
Bid
130.99
Ask
131.34
Volume
143,134
127.7492 Day's Range 133.80
0.00 52 Week Range 0.00
Market Cap
Previous Close
133.00
Open
132.60
Last Trade
20
@
131.33
Last Trade Time
14:56:36
Financial Volume
$ 18,594,223
VWAP
129.9078
Average Volume (3m)
-
Shares Outstanding
56,614,385
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-
Revenue
200.64M
Net Profit
-481.45M

About Ascendis Pharma AS

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and ... Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Hellerup, Dnk
Founded
-
Ascendis Pharma AS is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ASND. The last closing price for Ascendis Pharma AS was $133. Over the last year, Ascendis Pharma AS shares have traded in a share price range of $ 0.00 to $ 0.00.

Ascendis Pharma AS currently has 56,614,385 shares outstanding. The market capitalization of Ascendis Pharma AS is $7.53 billion.

ASND Latest News

Ascendis Pharma Reports Third Quarter 2024 Financial Results

– YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3 – TransCon CNP NDA submission for achondroplasia planned for Q1...

Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

COPENHAGEN, Denmark, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report third quarter 2024 financial results and provide a business update on...

Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases

-  Collaboration leverages Ascendis’ proprietary TransCon™ technologies and Novo Nordisk’s expertise in cardiometabolic diseases -  Once-monthly GLP-1 receptor agonist will be the collaboration’s...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LDTCLeddarTech Holdings Inc
$ 1.475
(375.50%)
263.06M
MGXMetagenomi Inc
$ 4.1501
(124.33%)
53M
ZEOZeo Energy Corporation
$ 2.59
(97.71%)
46.66M
HUIZHuize Holding Ltd
$ 4.94
(82.94%)
3.11M
GXAIGaxos ai Inc
$ 4.54
(74.62%)
103.06M
BIOABioAge Labs Inc
$ 4.995
(-75.14%)
8M
UPCUniverse Pharmaceuticals Inc
$ 1.345
(-60.32%)
4.66M
RADXRadiopharm Theranostics Ltd
$ 9.88
(-47.72%)
95.65k
CYNCYNGN Inc
$ 4.01
(-32.72%)
756.71k
BSGMBioSig Technologies Inc
$ 0.99
(-30.28%)
272.76k
RIMEAlgorhythm Holdings Inc
$ 0.121
(31.52%)
264.54M
LDTCLeddarTech Holdings Inc
$ 1.47
(373.89%)
263.06M
DUOFangDD Network Group Ltd
$ 0.8321
(43.91%)
252.16M
UOKAMDJM Ltd
$ 0.2243
(54.37%)
228.66M
LCIDLucid Group Inc
$ 2.565
(11.52%)
150.73M

ASND Discussion

View Posts
Monksdream Monksdream 9 months ago
ASND new 52=week high
👍️0
Monksdream Monksdream 10 months ago
ASND new 52 week high
👍️0
MiamiGent MiamiGent 10 months ago
What goes down, must go up :)
Hope you banked, monk.
👍️0
Monksdream Monksdream 10 months ago
ASND new 52 week high
👍️0
Monksdream Monksdream 11 months ago
ASND new 52 week high
👍️0
MiamiGent MiamiGent 2 years ago
ASND 161 shares traded in pre-mkt. Take your profits- nobody going to hold up this dilution candidate.
Bearish
👍️0
MiamiGent MiamiGent 2 years ago
ASND After just one day of wooing, ASND is FALLING ...........in love with my short.
Irresistible attraction: fourteen-month delay on average, need for more money and a red market with housing assuring further rate increase.
Quote as of 5/02/2023 2:44PM ET
$86.375 -$0.365 (-0.421%)
Bearish
https://www.bing.com/videos/search?q=you+tube+music+roy+orbison+i%27m+falling&view=detail&mid=17436B40AE02F042D00317436B40AE02F042D003&FORM=VIRE
👍️0
MiamiGent MiamiGent 2 years ago
$ASND
A complete response letter (CRL) from the FDA delays a product’s entry to the market by an average of 14 months. Companies that receive the letters take an average of seven months just to respond to them.
FDA NEWS
Bearish
👍️0
MiamiGent MiamiGent 2 years ago
ASND Net Income -$622,419,000 in 2022

Anyone want to venture a guess when the raise will come?

I'll take a WAG and say within two weeks.
👍️0
MiamiGent MiamiGent 2 years ago
ASND Quote as of 5/02/2023 10:14AM ET

$88.07 +$1.33 (+1.533%)

I'm down -3.22% on my short. Did not choose well- 100% owned by institutions.. not easily budged.
I am counting on red days, 3 day rule, CRL and outside chance of a raise- it's all I got, lol

https://stockcharts.com/h-sc/ui?s=ASND
👍️0
MiamiGent MiamiGent 2 years ago
Short today at 85.34

How long will this languish before possible good news?

Will need to raise more $$
👍️0
crudeoil24 crudeoil24 3 years ago
Ascendis Pharma: FDA Approves Skytrofa to Treat Pediatric Growth Hormone Deficiency > ASND
3:46 pm ET August 25, 2021

By Stephen Nakrosis

Ascendis Pharma A/S on Wednesday said the U.S. Food and Drug Administration approved its Skytrofa as a treatment for Pediatric Growth Hormone Deficiency.

The company said Skytrofa, or lonapegsomatropin-tcgd, is the first once-weekly treatment approved to treat Pediatric Growth Hormone Deficiency.

The company also said Skytrofa was approved to treat "pediatric patients one year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone."

The company said the approval includes its Skytrofa Auto-Injector and cartridges, which enable families to store the medicine at room temperature for up to six months.

The company said availability of Skytrofa in the U.S. is expected soon.

Ascendis said it would hold an investor conference call at 4:30 p.m. ET today.


Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
👍️0
crudeoil24 crudeoil24 3 years ago

ASCENDIS PHARMA A/S is a Danish-based biopharmaceutical company, which is involved in manufacture products for rare diseases. The Company utilizes its TransCon technologies for treatment, which can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs. The Company is headquartered in Copenhagen, Denmark with offices in Heidelberg, Germany and Palo Alto, California.
👍️0

Your Recent History

Delayed Upgrade Clock